Tocilizumab as a potential therapeutic option for children with severe, refractory juvenile localized scleroderma

Rheumatology (Oxford). 2018 Feb 1;57(2):398-401. doi: 10.1093/rheumatology/kex382.

Authors

Hanna Lythgoe^{1

2

3}, Eileen Baildam¹, Michael W Beresford^{1

2

3}, Gavin Cleary¹, Liza J McCann¹, Clare E Pain¹

Affiliations

¹ Department of Paediatric Rheumatology, Liverpool, UK.
² NIHR Alder Hey Clinical Research Facility, Alder Hey Children's NHS Foundation Trust, Liverpool, UK.
³ Department of Women's and Children's, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.

PMID: 29077971
DOI: 10.1093/rheumatology/kex382

No abstract available

Publication types

Evaluation Study
Letter

MeSH terms

Adolescent
Antibodies, Monoclonal, Humanized / therapeutic use*
Child
Dermatologic Agents / therapeutic use*
Female
Humans
Male
Prospective Studies
Scleroderma, Localized / drug therapy*
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
Dermatologic Agents
tocilizumab